IN THE NEWS: FDA Approves Brentuximab Vedotin for DLBCL

Patient Power

Adult patients with relapsed or refractory large B-cell lymphoma now have access to the FDA-approved drug, brentuximab vedotin (BV). This new approval has extended the use of BV with lenalidomide and rituximab for patients who have had two or more lines of therapy and are ineligible for transplantation. José Larios, M.D., transplant hematologist and member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidisciplinary Teams at Karmanos, explained how the drug works and fits into the current treatment landscape.

Read the article here.

José Larios, M.D.